Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY19 results · Apr–Jun 2018
Aarti Drugs reported revenue from operations of ₹374.29 crore and net profit of ₹23.37 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 374.29 | — | — | — | — |
| Other income | 0.92 | — | — | — | — |
| Total income | 375.21 | — | — | — | — |
| Profit before tax | 33.72 | — | — | — | — |
| Net profit for the period | 23.37 | — | — | — | — |
| EPS, basic (₹) | 9.82 | — | — | — | — |
| Net margin (%) | 6.2 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 351.55 | — | — | — | — |
| Other income | 0.92 | — | — | — | — |
| Total income | 352.47 | — | — | — | — |
| Profit before tax | 32.39 | — | — | — | — |
| Net profit for the period | 22.39 | — | — | — | — |
| EPS, basic (₹) | 9.40 | — | — | — | — |
| Net margin (%) | 6.4 | — | — |
Consolidated
- Filed with BSE
- 17 Aug 2018, 15:23 IST
- Board meeting
- 13 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Aug 2018, 15:23 IST
- Board meeting
- 13 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Audited
- Source
- XBRL filing on BSE